Glaukos Corporation (GKOS) and InfuSystem Holdings Inc. (NYSEAMERICAN:INFU) Comparison side by side

Both Glaukos Corporation (NYSE:GKOS) and InfuSystem Holdings Inc. (NYSEAMERICAN:INFU) are Medical Instruments & Supplies companies, competing one another. We will compare their analyst recommendations, institutional ownership, profitability, risk, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Glaukos Corporation 195.17M 13.68 11.58M -0.37 0.00
InfuSystem Holdings Inc. 68.85M 1.30 2.26M -0.05 0.00

We can see in table 1 the earnings per share, top-line revenue and valuation of Glaukos Corporation and InfuSystem Holdings Inc.

Profitability

Table 2 represents Glaukos Corporation (NYSE:GKOS) and InfuSystem Holdings Inc. (NYSEAMERICAN:INFU)’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
Glaukos Corporation -5.93% -6.9% -5.8%
InfuSystem Holdings Inc. -3.28% -4.3% -1.7%

Volatility and Risk

Glaukos Corporation’s 1.54 beta indicates that its volatility is 54.00% more volatile than that of Standard and Poor’s 500. InfuSystem Holdings Inc.’s 0.21 beta is the reason why it is 79.00% less volatile than Standard and Poor’s 500.

Liquidity

Glaukos Corporation’s Current Ratio and Quick Ratio are 6.7 and 6.2 respectively. The Current Ratio and Quick Ratio of its competitor InfuSystem Holdings Inc. are 1.2 and 1 respectively. Glaukos Corporation therefore has a better chance of paying off short and long-term obligations compared to InfuSystem Holdings Inc.

Analyst Ratings

The next table highlights the given recommendations and ratings for Glaukos Corporation and InfuSystem Holdings Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Glaukos Corporation 0 2 2 2.50
InfuSystem Holdings Inc. 0 0 0 0.00

The consensus price target of Glaukos Corporation is $74.75, with potential upside of 1.94%.

Institutional and Insider Ownership

Institutional investors held 0% of Glaukos Corporation shares and 66.8% of InfuSystem Holdings Inc. shares. Insiders held 0.9% of Glaukos Corporation shares. Competitively, 19% are InfuSystem Holdings Inc.’s share held by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Glaukos Corporation -8.47% -11.57% -2.32% 9.74% 105.47% 19.73%
InfuSystem Holdings Inc. 5.15% -0.42% 18.69% 55.63% 64.91% 36.63%

For the past year Glaukos Corporation was less bullish than InfuSystem Holdings Inc.

Summary

On 7 of the 11 factors InfuSystem Holdings Inc. beats Glaukos Corporation.

Glaukos Corporation, an ophthalmic medical technology company, focuses on the development and commercialization of products and procedures designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. The companyÂ’s product pipeline includes iStent Inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry with the goal of achieving intraocular pressure reduction; iStent Supra suprachoroidal micro-bypass stent, which is designed to reduce intraocular pressure by accessing the suprachoroidal space in the eye; and iDose, a targeted injectable drug delivery implant that is designed to be pre-loaded into a small gauge needle and injected into the eye through a self-sealing corneal needle penetration. It markets its products through direct sales force in the United States and internationally, as well as through distribution partners in Europe, the Asia Pacific, and internationally. Glaukos Corporation was founded in 1998 and is headquartered in San Clemente, California.

InfuSystem Holdings Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology clinics, infusion clinics, hospital outpatient, and chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole mounted and ambulatory infusion pumps; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other alternate site settings comprising home care and home infusion providers, skilled nursing facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. InfuSystem Holdings Inc. was founded in 2005 and is headquartered in Madison Heights, Michigan.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.